STAT3 axis in cancer and cancer stem cells: From oncogenesis to targeted therapies
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2025
DOI: 10.1016/j.bbcan.2025.189461 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2025. Verfasst von Deepika Godugu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, New York, NY, USA. Hauptthemen laut MEDLINE: STAT3 Transcription Factor, Neoplastic Stem Cells, Neoplasms, Carcinogenesis. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 185 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Department of Pharmaceutical Sciences, St. John's University, St. John's University.
Abstract (Originalsprache)
The signal transducer and activator of transcription 3 (STAT3) is a cytoplasmic transcription factor that is essential in regulating cellular homeostasis. Aberrant and persistent activation of STAT3 triggers the oncogenic progression of multiple cancers. STAT3 can be activated by both canonical and non-canonical pathways, leading to its nuclear translocation and regulation of the transcription of multiple target genes to promote tumor cell proliferation, drug resistance, differentiation, inflammation, immune evasion, and angiogenesis. Persistent activation of STAT3 correlates with the poor prognosis of cancer patients. Notably, STAT3 plays a crucial role in the maintenance of cancer stem cells (CSCs), contributing to disease relapse, metastasis, and poor clinical outcomes. Given its multifaceted role in tumor biology, STAT3 is an attractive target for therapeutic intervention. Various small molecules, peptides, and natural compounds targeting STAT3 are currently under different stages of preclinical and clinical evaluation. Despite promising advances, challenges such as drug resistance, selectivity, and toxicity remain obstacles in the development of effective STAT3-targeted therapies. This review provides a comprehensive overview of STAT3 structure, activation mechanisms, and its functional role in tumor biology and CSC maintenance. We also highlight current progress in STAT3-targeted therapeutic strategies, including agents in clinical trials, and discuss the future potential of STAT3 inhibition in precision oncology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, New York, NY, USA.
- Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, New York, NY, USA. Electronic address: agarwals@stjohns.edu.
Förderung
- NCI NIH HHS
- Department of Pharmaceutical Sciences, St. John's University
- St. John's University
- St. Baldrick's Foundation
Zitieren
APA
Godugu, D., Chilamakuri, R., & Agarwal, S. (2025). STAT3 axis in cancer and cancer stem cells: From oncogenesis to targeted therapies. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. https://doi.org/10.1016/j.bbcan.2025.189461
Vancouver
Godugu D, Chilamakuri R, Agarwal S. STAT3 axis in cancer and cancer stem cells: From oncogenesis to targeted therapies. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2025. doi:10.1016/j.bbcan.2025.189461
BibTeX
@article{Godugu2025,
author = {Godugu, Deepika and Chilamakuri, Rameswari and Agarwal, Saurabh},
title = {STAT3 axis in cancer and cancer stem cells: From oncogenesis to targeted therapies},
journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
year = {2025},
doi = {10.1016/j.bbcan.2025.189461}
}
EUVIMED